BamSEC and AlphaSense Join Forces
Learn More

Liquidia Corporation – Material Contracts

NASDAQ: LQDA    
Share price (7/7/26): $81.23    
Market cap (7/7/26): $7.224 billion

Material Contracts Filter

EX-10.55
from 10-K 44 pages License Agreement
12/34/56
EX-10.14
from 10-K 2 pages Amendment to Restricted Stock Units Agreement
12/34/56
EX-10.13
from 10-K ~5 pages Amendment to Restricted Stock Units Notice
12/34/56
EX-10.12
from 10-K ~5 pages Liquidia Corporation Amendment to Stock Option Agreement Whereas, Liquidia Corporation (The “Company”) Maintains the Liquidia Corporation 2020 Long-Term Incentive Plan (The “Plan”) for the Benefit of Its Eligible Employees, Officers and Other Individuals, Including Non-Employee Directors, Who Perform Services for the Company or Its Subsidiaries; Whereas, the Company Desires to Amend the Stock Option Agreement (The “Agreement”) to Provide That the Vesting of All Outstanding Stock Options Granted Under the Plan (The “Outstanding Options”) Will Vest in Full on the Date of Death of the Respective Grantee; ​ Whereas, Section 15(b) of the Plan Provides That the Board of Directors of the Company or the Compensation Committee May Amend the Outstanding Options Without Grantee Consent; Provided That, Such Amendment Does Not Materially Impair the Grantee’s Rights With Respect to the Outstanding Options. ​ Now, Therefore, as of December 18, 2025, the Agreement Is Hereby Amended as Follows: ​ 1. Section 2(a) of the Agreement Is Hereby Amended to Add the Following Sentence to the End Thereof: “Notwithstanding Anything to the Contrary Herein, if Your Service With the Company Terminates Due to Your Death, Any Portion of the Option That Is Not Vested on Your Date of Death Will Become Fully Vested as of Such Date.” ​ 2. Section 3(a) Is Hereby Deleted and Replaced With the Following: ​ “If Your Service With the Company Ceases for Any Reason Other Than on Account of Your Death as Specified in Section 2(a) Above, the Options That Are Then Unexercisable Will Terminate Immediately Upon Such Cessation.” ​ 3. in All Respects Not Amended, the Agreement Is Hereby Ratified and Confirmed. ​ Liquidia Corporation ​ ​ ​ /S/ Roger A. Jeffs Roger A. Jeffs Title: Chief Executive Officer 1626629025.1 ​
12/34/56
EX-10.11
from 10-K 1 page Liquidia Corporation ​ Amendment to Stock Option Grant Notice
12/34/56
EX-10.1
from 10-Q 113 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. ​ Pathway Triangle 1000 Science Drive Morrisville, North Carolina Lease Summary Sheet
12/34/56
EX-10.53
from 10-K 2 pages January 7, 2025 ​
12/34/56
EX-10.25
from 10-K 13 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Sixth Amendment to the Revenue Interest Financing Agreement
12/34/56
EX-10.5
from 10-Q 7 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted
12/34/56
EX-10.4
from 10-Q 49 pages Device License Agreement Dated as of October 2, 2024 by and Between Pharmosa Biopharm Inc. and Liquidia Technologies, Inc
12/34/56
EX-10.3
from 8-K 10 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Fifth Amendment to the Revenue Interest Financing Agreement
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 33 pages Common Stock Purchase Agreement
12/34/56
EX-10.1
from 8-K 31 pages Liquidia Corporation Amended and Restated Executive Severance and Change in Control Plan
12/34/56
EX-10.50
from 10-K 11 pages Asset Transfer Agreement
12/34/56
EX-10.51
from 10-K 21 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. ​ Supply Agreement
12/34/56
EX-10.49
from 10-K 71 pages License Agreement Dated as of June 28, 2023 by and Between Pharmosa Biopharm Inc. and Liquidia Technologies, Inc
12/34/56
EX-10.47
from 10-K 23 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. ​ Amended and Restated Commercial Manufacturing Services and Supply Agreement
12/34/56
EX-10.20
from 10-K 11 pages ​ Third Amendment to the Revenue Interest Financing Agreement
12/34/56
EX-10.19
from 10-K 7 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Second Amendment to the Revenue Interest Financing Agreement
12/34/56